Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Chugai Pharmaceutical Co ( (JP:4519) ) has issued an announcement.
Chugai Pharmaceutical has approved detailed terms for a new trust-based stock compensation framework for its directors and those of its subsidiaries, following shareholder approval of a revised compensation system in March 2026. Under an Executive Compensation BIP Trust, the company will allocate up to ¥1.86 billion to acquire its own common shares on the market between May 1 and the end of May 2026, with the trust running through May 2030 and serving as an incentive scheme for executive directors.
In parallel, Chugai will establish a Stock Grant ESOP Trust for executive officers and employees of the company and its subsidiaries, funded with up to ¥2.5 billion for market purchases of Chugai common shares over the same period. By expanding equity-based incentives across management and staff, Chugai aims to better align internal stakeholders with shareholder interests and reinforce its long-term corporate value strategy without exercising voting rights on the shares held in trust.
The most recent analyst rating on (JP:4519) stock is a Buy with a Yen9800.00 price target. To see the full list of analyst forecasts on Chugai Pharmaceutical Co stock, see the JP:4519 Stock Forecast page.
More about Chugai Pharmaceutical Co
Chugai Pharmaceutical Co., Ltd. is a Japan-based pharmaceutical company listed on the Prime Market of the Tokyo Stock Exchange. The company develops and markets prescription drugs and related therapies, focusing on innovative medicines for domestic and global healthcare markets.
Average Trading Volume: 2,502,245
Technical Sentiment Signal: Buy
Current Market Cap: Yen14676.7B
For an in-depth examination of 4519 stock, go to TipRanks’ Overview page.